您的位置:PharmaNews 市场快讯 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Actient Pharmaceuticals, LLC Closes Transaction to License and Acquire Specialty Pharmaceutical Products from UCB, INC.(2)
本文章共1927字,分2页,当前第2页,快速翻页:

.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Healthcare, Financial Services & Technology, and Information Services & Technology industries. The Chicago-based firm pioneered the “Leaders Strategy” – finding and partnering with world-class leaders as the critical first step in identifying, acquiring and building market-leading companies through acquisitions and organic growth. Since its inception, GTCR has invested more than $8.0 billion in over 200 companies. For more information, please visit www.gtcr.com.

Contact: for Actient Pharmaceuticals, LLC
Media Contact:
Eileen Rochford
312-953-3305
eileenr@theharbingergroup.com

 转载自pharmaLive

 


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Access Pharmaceuticals to Host North Ame

  MCOs Offering Both Medicare Advantage an

  Sun Pharma: US Appeals Court Rules Gemza

  Marketing Disease Prevention In America

  Purdue Archives and Special Collections

Health Secretary Urges All Pennsylvanian

Sanofi Pasteur Begins Shipping Influenza

GlaxoSmithKline Begins Distribution of F

Perrigo Confirms Filing for Generic Vers

全球气温飙升,清凉油出口井喷

深度观察:新版医保药品目录调整导向透露出

中药饮片集采如箭在弦,质量成药企入局的头

医药板块四季度该怎么布局?业内推荐4条主线

全球医药产业链正在重塑 中国原料药产业行稳

第七批药品国采解读:48%药价降幅更理性,

相关评论

    
本文章所属分类:首页 市场快讯